Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Jan;36(1):1–5. doi: 10.1128/aac.36.1.1

Use of immune modulators in nonspecific therapy of bacterial infections.

M T Vogels 1, J W van der Meer 1
PMCID: PMC189216  PMID: 1590674

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adlam C., Broughton E. S., Scott M. T. Enhanced resistance of mice to infection with bacteria following pre-treatment with Corynebacterium parvum. Nat New Biol. 1972 Feb 16;235(59):219–220. doi: 10.1038/newbio235219a0. [DOI] [PubMed] [Google Scholar]
  2. Apte R. N., Galanos C., Pluznik D. H. Lipid A, the active part of bacterial endotoxins in inducing serum colony stimulating activity and proliferation of splenic granulocyte/macrophage progenitor cells. J Cell Physiol. 1976 Jan;87(1):71–78. doi: 10.1002/jcp.1040870110. [DOI] [PubMed] [Google Scholar]
  3. Badaro R., Falcoff E., Badaro F. S., Carvalho E. M., Pedral-Sampaio D., Barral A., Carvalho J. S., Barral-Netto M., Brandely M., Silva L. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med. 1990 Jan 4;322(1):16–21. doi: 10.1056/NEJM199001043220104. [DOI] [PubMed] [Google Scholar]
  4. Berger F. M., Fukui G. M., Gustafson R. H., Rosselet J. P. Studies on the mechanism of protodyne-induced protection against microbial infections. Proc Soc Exp Biol Med. 1971 Nov;138(2):391–395. doi: 10.3181/00379727-138-35904. [DOI] [PubMed] [Google Scholar]
  5. Bermudez L. E., Young L. S. Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol. 1988 May 1;140(9):3006–3013. [PubMed] [Google Scholar]
  6. Beutler B., Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987 Feb 12;316(7):379–385. doi: 10.1056/NEJM198702123160705. [DOI] [PubMed] [Google Scholar]
  7. Blanchard D. K., Djeu J. Y., Klein T. W., Friedman H., Stewart W. E., 2nd Protective effects of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function. J Leukoc Biol. 1988 May;43(5):429–435. doi: 10.1002/jlb.43.5.429. [DOI] [PubMed] [Google Scholar]
  8. Cannon J. G., Tompkins R. G., Gelfand J. A., Michie H. R., Stanford G. G., van der Meer J. W., Endres S., Lonnemann G., Corsetti J., Chernow B. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis. 1990 Jan;161(1):79–84. doi: 10.1093/infdis/161.1.79. [DOI] [PubMed] [Google Scholar]
  9. Chong K. T. Prophylactic administration of interleukin-2 protects mice from lethal challenge with gram-negative bacteria. Infect Immun. 1987 Mar;55(3):668–673. doi: 10.1128/iai.55.3.668-673.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Choromanski L., Kuhn R. E. Interleukin 2 enhances specific and nonspecific immune responses in experimental Chagas' disease. Infect Immun. 1985 Nov;50(2):354–357. doi: 10.1128/iai.50.2.354-357.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Clark I. A., Hunt N. H., Butcher G. A., Cowden W. B. Inhibition of murine malaria (Plasmodium chabaudi) in vivo by recombinant interferon-gamma or tumor necrosis factor, and its enhancement by butylated hydroxyanisole. J Immunol. 1987 Nov 15;139(10):3493–3496. [PubMed] [Google Scholar]
  12. Cluff L. E. Effects of endotoxins on susceptibility to infections. J Infect Dis. 1970 Sep;122(3):205–215. doi: 10.1093/infdis/122.3.205. [DOI] [PubMed] [Google Scholar]
  13. Curfs J. H., van der Meer J. W., Sauerwein R. W., Eling W. M. Low dosages of interleukin 1 protect mice against lethal cerebral malaria. J Exp Med. 1990 Nov 1;172(5):1287–1291. doi: 10.1084/jem.172.5.1287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Czuprynski C. J., Brown J. F., Young K. M., Cooley A. J., Kurtz R. S. Effects of murine recombinant interleukin 1 alpha on the host response to bacterial infection. J Immunol. 1988 Feb 1;140(3):962–968. [PubMed] [Google Scholar]
  15. DUBOS R. J., SCHAEDLER R. W. Effects of cellular constituents of mycobacteria on the resistance of mice to heterologous infections I. Protective effects. J Exp Med. 1957 Nov 1;106(5):703–717. doi: 10.1084/jem.106.5.703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. De Titto E. H., Catterall J. R., Remington J. S. Activity of recombinant tumor necrosis factor on Toxoplasma gondii and Trypanosoma cruzi. J Immunol. 1986 Aug 15;137(4):1342–1345. [PubMed] [Google Scholar]
  17. Desiderio J. V., Kiener P. A., Lin P. F., Warr G. A. Protection of mice against Listeria monocytogenes infection by recombinant human tumor necrosis factor alpha. Infect Immun. 1989 May;57(5):1615–1617. doi: 10.1128/iai.57.5.1615-1617.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Dinarello C. A. Biology of interleukin 1. FASEB J. 1988 Feb;2(2):108–115. [PubMed] [Google Scholar]
  19. Djeu J. Y., Blanchard D. K., Halkias D., Friedman H. Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-gamma and tumor necrosis factor. J Immunol. 1986 Nov 1;137(9):2980–2984. [PubMed] [Google Scholar]
  20. Elin R. J., Wolff S. M. The role of iron in nonspecific resistance to infection induced by endotoxin. J Immunol. 1974 Feb;112(2):737–745. [PubMed] [Google Scholar]
  21. Fanslow W. C., Sims J. E., Sassenfeld H., Morrissey P. J., Gillis S., Dower S. K., Widmer M. B. Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science. 1990 May 11;248(4956):739–742. doi: 10.1126/science.2139736. [DOI] [PubMed] [Google Scholar]
  22. Frenck R. W., Sarman G., Harper T. E., Buescher E. S. The ability of recombinant murine granulocyte-macrophage colony-stimulating factor to protect neonatal rats from septic death due to Staphylococcus aureus. J Infect Dis. 1990 Jul;162(1):109–114. doi: 10.1093/infdis/162.1.109. [DOI] [PubMed] [Google Scholar]
  23. Fujiki T., Tanaka A. Antibacterial activity of recombinant murine beta interferon. Infect Immun. 1988 Mar;56(3):548–551. doi: 10.1128/iai.56.3.548-551.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Goronzy J., Weyand C., Quan J., Fathman C. G., O'Hanley P. Enhanced cell-mediated protection against fatal Escherichia coli septicemia induced by treatment with recombinant IL-2. J Immunol. 1989 Feb 15;142(4):1134–1138. [PubMed] [Google Scholar]
  25. Green S., Dobrjansky A., Chiasson M. A., Carswell E., Schwartz M. K., Old L. J. Corynebacterium parvum as the priming agent in the production of tumor necrosis factor in the mouse. J Natl Cancer Inst. 1977 Nov;59(5):1519–1522. doi: 10.1093/jnci/59.5.1519. [DOI] [PubMed] [Google Scholar]
  26. Haak-Frendscho M., Young K. M., Czuprynski C. J. Treatment of mice with human recombinant interleukin-2 augments resistance to the facultative intracellular pathogen Listeria monocytogenes. Infect Immun. 1989 Oct;57(10):3014–3021. doi: 10.1128/iai.57.10.3014-3021.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Hannum C. H., Wilcox C. J., Arend W. P., Joslin F. G., Dripps D. J., Heimdal P. L., Armes L. G., Sommer A., Eisenberg S. P., Thompson R. C. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature. 1990 Jan 25;343(6256):336–340. doi: 10.1038/343336a0. [DOI] [PubMed] [Google Scholar]
  28. Hauser T., Frei K., Zinkernagel R. M., Leist T. P. Role of tumor necrosis factor in Listeria resistance of nude mice. Med Microbiol Immunol. 1990;179(2):95–104. doi: 10.1007/BF00198530. [DOI] [PubMed] [Google Scholar]
  29. Havell E. A. Production of tumor necrosis factor during murine listeriosis. J Immunol. 1987 Dec 15;139(12):4225–4231. [PubMed] [Google Scholar]
  30. Hebert J. C., O'Reilly M., Gamelli R. L. Protective effect of recombinant human granulocyte colony-stimulating factor against pneumococcal infections in splenectomized mice. Arch Surg. 1990 Aug;125(8):1075–1078. doi: 10.1001/archsurg.1990.01410200141022. [DOI] [PubMed] [Google Scholar]
  31. Hefeneider S. H., Conlon P. J., Henney C. S., Gillis S. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J Immunol. 1983 Jan;130(1):222–227. [PubMed] [Google Scholar]
  32. Hershman M. J., Pietsch J. D., Trachtenberg L., Mooney T. H., Shields R. E., Sonnenfeld G. Protective effects of recombinant human tumour necrosis factor alpha and interferon gamma against surgically simulated wound infection in mice. Br J Surg. 1989 Dec;76(12):1282–1286. doi: 10.1002/bjs.1800761220. [DOI] [PubMed] [Google Scholar]
  33. Holtmann H., Wallach D. Down regulation of the receptors for tumor necrosis factor by interleukin 1 and 4 beta-phorbol-12-myristate-13-acetate. J Immunol. 1987 Aug 15;139(4):1161–1167. [PubMed] [Google Scholar]
  34. Iida J., Saiki I., Ishihara C., Azuma I. Protective activity of recombinant cytokines against Sendai virus and herpes simplex virus (HSV) infections in mice. Vaccine. 1989 Jun;7(3):229–233. doi: 10.1016/0264-410x(89)90234-x. [DOI] [PubMed] [Google Scholar]
  35. Iizawa Y., Nakao M., Kondo M., Yamazaki T. Protective effect of recombinant human interleukin-2 against lethal infection caused by Klebsiella pneumoniae. Microbiol Immunol. 1990;34(2):185–195. doi: 10.1111/j.1348-0421.1990.tb01003.x. [DOI] [PubMed] [Google Scholar]
  36. Klempner M. S., Noring R., Mier J. W., Atkins M. B. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med. 1990 Apr 5;322(14):959–965. doi: 10.1056/NEJM199004053221404. [DOI] [PubMed] [Google Scholar]
  37. Kradin R., Yamin R., Kurnick J. Immunological effects of adoptive immunotherapy with IL-2: an overview. Pathol Immunopathol Res. 1988;7(6):434–441. doi: 10.1159/000157073. [DOI] [PubMed] [Google Scholar]
  38. Kullberg B. J., van 't Wout J. W., van Furth R. Role of granulocytes in increased host resistance to Candida albicans induced by recombinant interleukin-1. Infect Immun. 1990 Oct;58(10):3319–3324. doi: 10.1128/iai.58.10.3319-3324.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Matsumoto M., Matsubara S., Matsuno T., Tamura M., Hattori K., Nomura H., Ono M., Yokota T. Protective effect of human granulocyte colony-stimulating factor on microbial infection in neutropenic mice. Infect Immun. 1987 Nov;55(11):2715–2720. doi: 10.1128/iai.55.11.2715-2720.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. McIntyre K. W., Unowsky J., DeLorenzo W., Benjamin W. Enhancement of antibacterial resistance of neutropenic, bone marrow-suppressed mice by interleukin-1 alpha. Infect Immun. 1989 Jan;57(1):48–54. doi: 10.1128/iai.57.1.48-54.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Minami A., Fujimoto K., Ozaki Y., Nakamura S. Augmentation of host resistance to microbial infections by recombinant human interleukin-1 alpha. Infect Immun. 1988 Dec;56(12):3116–3120. doi: 10.1128/iai.56.12.3116-3120.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Morikage T., Mizushima Y., Sakamoto K., Yano S. Prevention of fatal infections by recombinant human interleukin 1 alpha in normal and anticancer drug-treated mice. Cancer Res. 1990 Apr 1;50(7):2099–2104. [PubMed] [Google Scholar]
  43. Munker R., Gasson J., Ogawa M., Koeffler H. P. Recombinant human TNF induces production of granulocyte-monocyte colony-stimulating factor. Nature. 1986 Sep 4;323(6083):79–82. doi: 10.1038/323079a0. [DOI] [PubMed] [Google Scholar]
  44. Murray H. W. Gamma interferon, cytokine-induced macrophage activation, and antimicrobial host defense. In vitro, in animal models, and in humans. Diagn Microbiol Infect Dis. 1990 Sep-Oct;13(5):411–421. doi: 10.1016/0732-8893(90)90012-k. [DOI] [PubMed] [Google Scholar]
  45. Nakano Y., Onozuka K., Terada Y., Shinomiya H., Nakano M. Protective effect of recombinant tumor necrosis factor-alpha in murine salmonellosis. J Immunol. 1990 Mar 1;144(5):1935–1941. [PubMed] [Google Scholar]
  46. Nawroth P. P., Bank I., Handley D., Cassimeris J., Chess L., Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med. 1986 Jun 1;163(6):1363–1375. doi: 10.1084/jem.163.6.1363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Ozaki Y., Ohashi T., Minami A., Nakamura S. Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-1a. Infect Immun. 1987 Jun;55(6):1436–1440. doi: 10.1128/iai.55.6.1436-1440.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Parant M. Effects of TNF in bacterial infections. Ann Inst Pasteur Immunol. 1988 May-Jun;139(3):301–304. doi: 10.1016/0769-2625(88)90145-6. [DOI] [PubMed] [Google Scholar]
  49. Pelkonen S., Pluschke G. Recombinant interleukin-1 stimulates clearance of Escherichia coli K1 bacteraemia. Microb Pathog. 1989 Jun;6(6):415–424. doi: 10.1016/0882-4010(89)90083-1. [DOI] [PubMed] [Google Scholar]
  50. Reed S. G., Nathan C. F., Pihl D. L., Rodricks P., Shanebeck K., Conlon P. J., Grabstein K. H. Recombinant granulocyte/macrophage colony-stimulating factor activates macrophages to inhibit Trypanosoma cruzi and release hydrogen peroxide. Comparison with interferon gamma. J Exp Med. 1987 Dec 1;166(6):1734–1746. doi: 10.1084/jem.166.6.1734. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Ribeiro R. A., Cunha F. Q., Ferreira S. H. Recombinant gamma interferon causes neutrophil migration mediated by the release of a macrophage neutrophil chemotactic factor. Int J Exp Pathol. 1990 Oct;71(5):717–725. [PMC free article] [PubMed] [Google Scholar]
  52. Seckinger P., Isaaz S., Dayer J. M. A human inhibitor of tumor necrosis factor alpha. J Exp Med. 1988 Apr 1;167(4):1511–1516. doi: 10.1084/jem.167.4.1511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Sharma S. D., Hofflin J. M., Remington J. S. In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii. J Immunol. 1985 Dec;135(6):4160–4163. [PubMed] [Google Scholar]
  54. Sheppard B. C., Fraker D. L., Norton J. A. Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor. Surgery. 1989 Aug;106(2):156–162. [PubMed] [Google Scholar]
  55. Sisson S. D., Dinarello C. A. Production of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor. Blood. 1988 Oct;72(4):1368–1374. [PubMed] [Google Scholar]
  56. Van der Meer J. W., Helle M., Aarden L. Comparison of the effects of recombinant interleukin 6 and recombinant interleukin 1 on nonspecific resistance to infection. Eur J Immunol. 1989 Feb;19(2):413–416. doi: 10.1002/eji.1830190229. [DOI] [PubMed] [Google Scholar]
  57. Van't Wout J. W., Van der Meer J. W., Barza M., Dinarello C. A. Protection of neutropenic mice from lethal Candida albicans infection by recombinant interleukin 1. Eur J Immunol. 1988 Jul;18(7):1143–1146. doi: 10.1002/eji.1830180728. [DOI] [PubMed] [Google Scholar]
  58. Vecchiarelli A., Cenci E., Puliti M., Blasi E., Puccetti P., Cassone A., Bistoni F. Protective immunity induced by low-virulence Candida albicans: cytokine production in the development of the anti-infectious state. Cell Immunol. 1989 Dec;124(2):334–344. doi: 10.1016/0008-8749(89)90135-4. [DOI] [PubMed] [Google Scholar]
  59. Vogel S. N., Douches S. D., Kaufman E. N., Neta R. Induction of colony stimulating factor in vivo by recombinant interleukin 1 alpha and recombinant tumor necrosis factor alpha 1. J Immunol. 1987 Apr 1;138(7):2143–2148. [PubMed] [Google Scholar]
  60. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med. 1989 Jan 1;169(1):333–338. doi: 10.1084/jem.169.1.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Weinberg A., Rasmussen L., Merigan T. C. Acute genital infection in guinea pigs: effect of recombinant interleukin-2 on herpes simplex virus type 2. J Infect Dis. 1986 Jul;154(1):134–140. doi: 10.1093/infdis/154.1.134. [DOI] [PubMed] [Google Scholar]
  62. Westwick J., Li S. W., Camp R. D. Novel neutrophil-stimulating peptides. Immunol Today. 1989 May;10(5):146–147. doi: 10.1016/0167-5699(89)90164-3. [DOI] [PubMed] [Google Scholar]
  63. Williams D. L., Browder I. W., Di Luzio N. R. Immunotherapeutic modification of Escherichia coli--induced experimental peritonitis and bacteremia by glucan. Surgery. 1983 Mar;93(3):448–454. [PubMed] [Google Scholar]
  64. Wing E. J., Waheed A., Shadduck R. K., Nagle L. S., Stephenson K. Effect of colony stimulating factor on murine macrophages. Induction of antitumor activity. J Clin Invest. 1982 Feb;69(2):270–276. doi: 10.1172/JCI110449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Zueva V. S., Kuznetsov V. P., Spivak N. Ia, Avakian L. M. Podavlenie interferonom razvitiia stafilokokkovoi infektsii. Antibiot Med Biotekhnol. 1985 Nov;30(11):863–868. [PubMed] [Google Scholar]
  66. van der Meer J. W., Barza M., Wolff S. M., Dinarello C. A. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci U S A. 1988 Mar;85(5):1620–1623. doi: 10.1073/pnas.85.5.1620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. van der Meer J. W., Rubin R. H., Pasternack M., Medearis D. N., Lynch P., Dinarello C. A. The in vivo and in vitro effects of interleukin-1 and tumor necrosis factor on murine cytomegalovirus infection. Biotherapy. 1989;1(3):227–231. doi: 10.1007/BF02170891. [DOI] [PubMed] [Google Scholar]
  68. van der Meer J. W. The effects of recombinant interleukin-1 and recombinant tumor necrosis factor on non-specific resistance to infection. Biotherapy. 1988;1(1):19–25. doi: 10.1007/BF02170132. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES